ID   delta-47
AC   CVCL_2887
SY   Delta-47; DELTA-47; Delta 47; DELTA 47; Delta47; DELTA47
DR   Cosmic; 720783
DR   Cosmic; 760400
DR   Cosmic; 2081378
DR   Cosmic; 2302420
DR   Cosmic; 2367274
DR   Cosmic; 2391802
DR   JCRB; JCRB1344
DR   JCRB; NIHS0543
DR   SKY/M-FISH/CGH; 2517
DR   Wikidata; Q54830967
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1329502;
RX   PubMed=8943038;
RX   PubMed=10936422;
RX   PubMed=11157491;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=32123307;
WW   Info; Keats Lab; -; https://www.keatslab.org/myeloma-cell-lines
CC   Population: Japanese.
CC   Characteristics: Produces IgD lambda.
CC   Doubling time: 40 hours (PubMed=1329502).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5723; IGKJ5 + HGNC; HGNC:5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5723; IGKJ5 + HGNC; HGNC:5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ5 (CelloPub=CLPUB00604).
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Discontinued: JCRB; NIHS0543; true.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: Plasma cell; CL=CL_0000786.
ST   Source(s): JCRB=JCRB1344
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 9,11
ST   D5S818: 10,12
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8,10
ST   vWA: 14,20
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   73Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 23
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler, Hans Gunther
RA   Matsuo, Yoshinobu
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   CelloPub=CLPUB00604;
RA   Chow, Sharon
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017); University of Toronto; Toronto; Canada.
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300;
RA   Sarin, Vishesh
RA   Yu, Katharine
RA   Ferguson, Ian D.
RA   Gugliemini, Olivia
RA   Nix, Matthew A.
RA   Hann, Byron
RA   Sirota, Marina
RA   Wiita, Arun P.
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund, Helena
RA   Nilsson, Kenneth
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters, John R.W. & Palsson, Bernhard Orn (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler, Hans Gunther
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi, Marta
RA   Brents, Leslie A.
RA   Ely, Sarah A.
RA   Bais, Carlos
RA   Robbiani, Davide F.
RA   Mesri, Enrique A.
RA   Kuehl, Walter Michael
RA   Bergsagel, Peter Leif
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003; PMCID=PMC2083698;
RA   Keats, Jonathan J.
RA   Fonseca, Rafael
RA   Chesi, Marta
RA   Schop, Roelandt
RA   Baker, Angela
RA   Chng, Wee-Joo
RA   Van Wier, Scott
RA   Tiedemann, Rodger
RA   Shi, Chang-Xin
RA   Sebag, Michael
RA   Braggio, Esteban
RA   Henry, Travis
RA   Zhu, Yuan-Xiao
RA   Fogle, Homer
RA   Price-Troska, Tammy L.
RA   Ahmann, Gregory J.
RA   Mancini, Catherine
RA   Brents, Leslie A.
RA   Kumar, Shaji K.
RA   Greipp, Philip Robert
RA   Dispenzieri, Angela
RA   Bryant, Barb
RA   Mulligan, George
RA   Bruhn, Laurakay
RA   Barrett, Michael T.
RA   Valdez, Riccardo
RA   Trent, Jeffrey M.
RA   Stewart, A. Keith
RA   Carpten, John D.
RA   Bergsagel, Peter Leif
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184;
RA   Dib, Amel
RA   Gabrea, Ana
RA   Glebov, Oleg K.
RA   Bergsagel, Peter Leif
RA   Kuehl, Walter Michael
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=1329502; DOI=10.1002/ajh.2830410314;
RA   Ishii, Kazuyoshi
RA   Yamato, Kenji
RA   Kubonishi, Ichiro
RA   Taguchi, Hirokuni
RA   Ohtsuki, Yuji
RA   Miyoshi, Isao
RT   "IgD myeloma presenting as a testicular tumor: establishment and
RT   characterization of an IgD-secreting myeloma cell line.";
RL   Am. J. Hematol. 41:218-224(1992).
//
RX   PubMed=8943038; DOI=10.1073/pnas.93.24.13931; PMCID=PMC19472;
RA   Bergsagel, Peter Leif
RA   Chesi, Marta
RA   Nardini, Elena
RA   Brents, Leslie A.
RA   Kirby, Suzanne Lee
RA   Kuehl, Walter Michael
RT   "Promiscuous translocations into immunoglobulin heavy chain switch
RT   regions in multiple myeloma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
//